Survodutide, also known as BI 456906, is a dual glucagon/GLP-1 receptor agonist engineered for long-acting obesity therapy. Its dual action enhances both fat breakdown and appetite suppression, delivering superior weight reduction compared to GLP-1 monotherapies like semaglutide. Clinical trials have demonstrated consistent, dose-dependent results, with over half of participants achieving meaningful weight loss at doses of 2.4 mg or more. With promising efficacy in both diabetic and non-diabetic populations, survodutide is emerging as a strong candidate in next-generation metabolic therapies.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Survodutide by Stealth Labs, consult with your doctor or healthcare professional.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Home
